TAZ/Wnt-β-catenin/c-MYC axis regulates cystogenesis in polycystic kidney disease

Significance Autosomal-dominant polycystic kidney disease (ADPKD) is the most common genetic renal disease, primarily caused by germline mutation of PKD1 or PKD2, leading to end-stage renal disease. There are few cures for ADPKD, although many researchers are trying to find a cure. The Hippo signaling pathway regulates organ growth and cell proliferation. Transcriptional coactivator with PDZ-binding motif (TAZ) is a Hippo signaling effector. In this study, we demonstrated that the PKD1–TAZ–Wnt–β-catenin–c-MYC signaling axis plays a critical role in cystogenesis. Endo IWR1 treatment, which inhibited β-catenin activity via AXIN stabilization, reduced cyst growth in an ADPKD model. Our findings provide a potential therapeutic target against ADPKD and would be important for clinical translation. Autosomal-dominant polycystic kidney disease (ADPKD) is the most common genetic renal disease, primarily caused by germline mutation of PKD1 or PKD2, leading to end-stage renal disease. The Hippo signaling pathway regulates organ growth and cell proliferation. Herein, we demonstrate the regulatory mechanism of cystogenesis in ADPKD by transcriptional coactivator with PDZ-binding motif (TAZ), a Hippo signaling effector. TAZ was highly expressed around the renal cyst-lining epithelial cells of Pkd1-deficient mice. Loss of Taz in Pkd1-deficient mice reduced cyst formation. In wild type, TAZ interacted with PKD1, which inactivated β-catenin. In contrast, in PKD1-deficient cells, TAZ interacted with AXIN1, thus increasing β-catenin activity. Interaction of TAZ with AXIN1 in PKD1-deficient cells resulted in nuclear accumulation of TAZ together with β-catenin, which up-regulated c-MYC expression. Our findings suggest that the PKD1–TAZ–Wnt–β-catenin–c-MYC signaling axis plays a critical role in cystogenesis and might be a potential therapeutic target against ADPKD.

[1]  A. Boletta,et al.  Polycystin-1 Regulates Actomyosin Contraction and the Cellular Response to Extracellular Stiffness , 2019, Scientific Reports.

[2]  C. Murphy,et al.  YAP and TAZ are distinct effectors of corneal myofibroblast transformation , 2019, Experimental eye research.

[3]  D. Lim,et al.  YAP and TAZ Negatively Regulate Prox1 During Developmental and Pathologic Lymphangiogenesis , 2019, Circulation research.

[4]  C. O’Brien,et al.  The YAP/TAZ transcriptional co-activators have opposing effects at different stages of osteoblast differentiation. , 2018, Bone.

[5]  D. Hwang,et al.  YAP/TAZ Initiates Gastric Tumorigenesis via Upregulation of MYC. , 2018, Cancer research.

[6]  F. Qian,et al.  A RhoA–YAP–c-Myc signaling axis promotes the development of polycystic kidney disease , 2018, Genes & development.

[7]  B. Ren,et al.  The Hippo pathway effector proteins YAP and TAZ have both distinct and overlapping functions in the cell , 2018, The Journal of Biological Chemistry.

[8]  C. Mei,et al.  Scribble influences cyst formation in autosomal‐dominant polycystic kidney disease by regulating Hippo signaling pathway , 2018, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[9]  C. Liang,et al.  Canonical Wnt inhibitors ameliorate cystogenesis in a mouse ortholog of human ADPKD. , 2018, JCI insight.

[10]  Fachao Zhi,et al.  YAP triggers the Wnt/β-catenin signalling pathway and promotes enterocyte self-renewal, regeneration and tumorigenesis after DSS-induced injury , 2018, Cell Death & Disease.

[11]  Jeremy C. Smith,et al.  Polycystin-1 interacts with TAZ to stimulate osteoblastogenesis and inhibit adipogenesis , 2018, The Journal of clinical investigation.

[12]  U. Apte,et al.  Increased YAP Activation Is Associated With Hepatic Cyst Epithelial Cell Proliferation in ARPKD/CHF. , 2017, Gene expression.

[13]  Bo Hye Kim,et al.  Profiling of miRNAs and target genes related to cystogenesis in ADPKD mouse models , 2017, Scientific Reports.

[14]  D. Matallanas,et al.  Common and Distinctive Functions of the Hippo Effectors Taz and Yap in Skeletal Muscle Stem Cell Function , 2017, Stem Cells.

[15]  Soohong Min,et al.  The Hippo-Salvador signaling pathway regulates renal tubulointerstitial fibrosis , 2016, Scientific Reports.

[16]  R. Salomon,et al.  Novel NEK8 Mutations Cause Severe Syndromic Renal Cystic Dysplasia through YAP Dysregulation , 2016, PLoS genetics.

[17]  M. Sudol,et al.  TAZ Protein Accumulation Is Negatively Regulated by YAP Abundance in Mammalian Cells* , 2015, The Journal of Biological Chemistry.

[18]  K. Guan,et al.  YAP and TAZ: a nexus for Hippo signaling and beyond. , 2015, Trends in cell biology.

[19]  D. Nguyen,et al.  Neuregulin 1–activated ERBB4 interacts with YAP to induce Hippo pathway target genes and promote cell migration , 2014, Science Signaling.

[20]  Giuseppe Basso,et al.  YAP/TAZ Incorporation in the β-Catenin Destruction Complex Orchestrates the Wnt Response , 2014, Cell.

[21]  Xaralabos Varelas,et al.  The Hippo pathway effectors TAZ and YAP in development, homeostasis and disease , 2014, Development.

[22]  E. Olson,et al.  Hippo pathway effector Yap promotes cardiac regeneration , 2013, Proceedings of the National Academy of Sciences.

[23]  Cristian Coarfa,et al.  SOX2 regulates YAP1 to maintain stemness and determine cell fate in the osteo-adipo lineage. , 2013, Cell reports.

[24]  T. Pawson,et al.  Yap- and Cdc42-Dependent Nephrogenesis and Morphogenesis during Mouse Kidney Development , 2013, PLoS genetics.

[25]  K. Guan,et al.  The YAP and TAZ transcription co-activators: key downstream effectors of the mammalian Hippo pathway. , 2012, Seminars in cell & developmental biology.

[26]  C. Edelstein,et al.  Mammalian target of rapamycin inhibition in polycystic kidney disease: From bench to bedside , 2012, Kidney research and clinical practice.

[27]  M. Breuning,et al.  Altered Hippo signalling in polycystic kidney disease , 2011, The Journal of pathology.

[28]  Randy L. Johnson,et al.  Hippo Pathway Inhibits Wnt Signaling to Restrain Cardiomyocyte Proliferation and Heart Size , 2011, Science.

[29]  V. Patel Balancing the Wnts in polycystic kidney disease. , 2010, Journal of the American Society of Nephrology : JASN.

[30]  Frederic A. Fellouse,et al.  The Hippo pathway regulates Wnt/beta-catenin signaling. , 2010, Developmental cell.

[31]  Madeline A. Lancaster,et al.  Impaired Wnt–β-catenin signaling disrupts adult renal homeostasis and leads to cystic kidney ciliopathy , 2009, Nature Medicine.

[32]  V. Torres,et al.  Polycystic kidney disease. , 2009, Annual review of medicine.

[33]  Lawrence Lum,et al.  Small molecule-mediated disruption of Wnt-dependent signaling in tissue regeneration and cancer , 2008, Nature chemical biology.

[34]  L. Cantley,et al.  Cyst formation and activation of the extracellular regulated kinase pathway after kidney specific inactivation of Pkd1. , 2008, Human molecular genetics.

[35]  H. Aburatani,et al.  Multiple renal cysts, urinary concentration defects, and pulmonary emphysematous changes in mice lacking TAZ. , 2008, American journal of physiology. Renal physiology.

[36]  Y. Shaul,et al.  The Yes-associated protein 1 stabilizes p73 by preventing Itch-mediated ubiquitination of p73 , 2007, Cell Death and Differentiation.

[37]  H. Ko,et al.  Glomerulocystic kidney disease in mice with a targeted inactivation of Wwtr1 , 2007, Proceedings of the National Academy of Sciences.

[38]  Y. Uchijima,et al.  Transcriptional activity of Pax3 is co-activated by TAZ. , 2006, Biochemical and biophysical research communications.

[39]  E. Olson,et al.  A WW domain protein TAZ is a critical coactivator for TBX5, a transcription factor implicated in Holt-Oram syndrome. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[40]  Pablo Tamayo,et al.  Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[41]  Thomas Benjamin,et al.  TAZ, a Transcriptional Modulator of Mesenchymal Stem Cell Differentiation , 2005, Science.

[42]  Albert C M Ong,et al.  Molecular pathogenesis of ADPKD: the polycystin complex gets complex. , 2005, Kidney international.

[43]  M. Yaffe,et al.  TAZ Interacts with TTF-1 and Regulates Expression of Surfactant Protein-C* , 2004, Journal of Biological Chemistry.

[44]  A. Kahn,et al.  Early development of polycystic kidney disease in transgenic mice expressing an activated mutant of the β-catenin gene , 2001, Oncogene.

[45]  V. D’Agati,et al.  C-myc as an inducer of polycystic kidney disease in transgenic mice. , 1991, Kidney international.

[46]  J. García Rodríguez,et al.  [Polycystic Kidney Disease]. , 2005, Actas urologicas espanolas.